Avalon Globocare Stock Price, News & Analysis

Avalon GloboCare Corp. (NASDAQ: ALBT) is described in its public communications as a commercial-stage company focused on precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. According to multiple company press releases, Avalon is marketing the KetoAir™ breathalyzer device, is working to develop additional diagnostic uses of this breathalyzer technology, and continues to build an intellectual property portfolio that includes CAR‑T and CAR‑NK cell technologies. In addition, Avalon states that it owns and operates commercial real estate, adding a real property component to its business.

The company’s disclosures highlight that KetoAir™ is a handheld breathalyzer designed for ketogenic health management. Company materials note that KetoAir™ measures breath acetone concentration (BrAce), a key indicator of fat metabolism and ketosis, and that the device utilizes nano‑sensor‑based technology. KetoAir™ is registered with the U.S. Food and Drug Administration as a Class I medical device, and is intended for individuals pursuing ketogenic diets for weight management, athletic performance, or therapeutic purposes. Avalon reports that KetoAir™ is compatible with both Apple and Android devices and is available via major mobile app stores.

Business segments and activities

Based on the company’s own descriptions, Avalon’s activities span several areas:

• Precision diagnostic consumer products – centered on the KetoAir™ breathalyzer, which Avalon is actively marketing in the United States and, through online channels, in the United Kingdom. Press releases describe distribution agreements, affiliate programs, and wellness initiatives that incorporate KetoAir™ as a monitoring and engagement tool.
• Cellular therapy intellectual property – Avalon reports that it is advancing intellectual property in cellular therapy, including proprietary CAR‑T and CAR‑Natural Killer (NK) cell technology. The company has announced issuance of a standard patent in Hong Kong for CAR‑T and CAR‑NK cell technology co‑developed with Arbele Limited, complementing patent protections in other jurisdictions referenced in its communications.
• Generative AI publishing and software – in company news and SEC filings, Avalon discloses the acquisition of RPM Interactive, Inc., a generative artificial intelligence publishing and software company. RPM has developed the Catch‑Up Software‑as‑a‑Service (SaaS) platform, which automatically sources video clips, generates AI commentary, creates an on‑screen avatar, and publishes short‑form video content.
• Real property operations – Avalon states that it owns and operates commercial real estate. Earlier descriptions also refer to a real property operating segment and a laboratory testing services segment, with real property identified as a key revenue driver at that time.

KetoAir™ breathalyzer and wellness programs

Company press releases describe KetoAir™ as a core product in Avalon’s precision diagnostics portfolio. KetoAir™ is characterized as a handheld device that measures breath acetone concentration to provide real‑time insights into ketosis and fat metabolism. Avalon reports that the device is used within structured wellness programs, including first‑responder‑focused initiatives such as the Nevada POOL/PACT Holistic Health Reset program and the BrAce 4 Impact Challenge, where participants use KetoAir™ for daily metabolic monitoring.

Through its subsidiary Q&A Distribution, LLC, Avalon has entered into a wholesale distribution agreement with Saga Health Corporation for the use of KetoAir™ in first responder wellness programs. The company also notes partnerships with organizations such as SpecialtyHealth, Inc. and Pounds Transformation in programs where KetoAir™ is integrated as a tool to help participants track ketone levels and support lifestyle changes.

Expansion and product development

In its disclosures, Avalon highlights several expansion and development efforts related to its diagnostic and technology assets:

• International availability of KetoAir™ – Avalon has announced that KetoAir™ and related accessories are offered for purchase in the United Kingdom through an online channel, which the company characterizes as its first international expansion of KetoAir™ marketing.
• Additional diagnostic uses of breathalyzer technology – the company repeatedly states that it plans to develop additional diagnostic uses of the breathalyzer technology beyond ketogenic health management.
• Co‑development of a cannabis breathalyzer – Avalon and Qi Diagnostics Limited have entered into a definitive agreement to co‑develop a volatile organic compound (VOC) nanosensor‑based point‑of‑care cannabis breathalyzer. According to the company, Avalon, its subsidiary Q&A Distribution, LLC, and Qi Diagnostics will jointly design, validate, and develop a prototype aimed at supporting real‑time detection of potential cannabis‑impaired driving.
• Use of generative AI for content creation – following the acquisition of RPM Interactive, Avalon reports that the Catch‑Up SaaS platform is expected to be licensed to content creators, media companies, and brands to generate recap‑style videos across categories such as news, politics, sports, finance, and entertainment, without manual editing or production tools.

Cellular therapy intellectual property

Avalon’s communications emphasize an ongoing focus on cellular therapy IP. The company has announced a Hong Kong patent for CAR‑T and CAR‑NK cell technology co‑developed with Arbele Limited. The patent is described as covering bispecific anti‑CD19xCD22 CAR designs and localized cytokine induction approaches intended to enhance CAR‑T and CAR‑NK cell manufacturing, expansion, survival, and therapeutic efficacy. Avalon notes that this patent complements existing patent protections in the United States and other jurisdictions under the Patent Cooperation Treaty, and that it continues to pursue additional patent applications as part of its intellectual property strategy.

Generative AI publishing and software

Through its acquisition of RPM Interactive, Avalon has added an AI‑driven software component to its business. Company disclosures explain that RPM’s Catch‑Up platform is a generative AI powered SaaS system that:

• Intelligently sources relevant video clips,
• Generates human‑like AI commentary,
• Creates an on‑screen avatar, and
• Publishes finished short‑form video content to major platforms on an automated basis.

Avalon has formed a subsidiary, Avalon Quantum AI, LLC, in connection with this acquisition. The company states that it plans to leverage the Catch‑Up platform to support and amplify marketing initiatives for KetoAir™, with the goal of increasing digital engagement around its consumer health products.

Corporate and capital markets context

Avalon’s shares trade on the Nasdaq Capital Market under the ticker symbol ALBT. The company has disclosed a variety of capital markets and corporate actions in its SEC filings, including senior secured promissory notes, preferred stock designations, and amendments to financing arrangements. In a press release, Avalon reported that it received notice from Nasdaq that it had regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement under Listing Rule 5550(b), and that its common stock would continue to be listed and traded on the Nasdaq Capital Market.

The company has also entered into an Agreement and Plan of Merger with YOOV Group Holding Limited, an Artificial Intelligence‑as‑a‑Service (AIaaS) platform specializing in intelligent business automation. According to joint communications, a Registration Statement on Form S‑4 has been filed in connection with the proposed merger, and the closing of the transaction is subject to conditions including stockholder approval and Nasdaq listing approval. Avalon notes that, if completed, the merger would result in a publicly traded company focused on AI‑enabled business automation, while Avalon continues to describe its existing activities in precision diagnostics, cellular therapy IP, and real estate.

Historical description and segments

Earlier descriptions of Avalon characterize it as an intelligent biotech developer and healthcare service provider, with two reportable segments: a real property operating segment, described as a key revenue driver at that time, and a laboratory testing services segment. Those descriptions also reference diagnostic and therapeutic focus areas such as early detection of certain cancers, skin regeneration and anti‑fibrosis, and treatments of degenerative disorders. More recent company communications, however, place particular emphasis on precision diagnostic consumer products, cellular therapy intellectual property, generative AI publishing and software, and commercial real estate ownership.

FAQs about Avalon GloboCare Corp. (ALBT)

• What does Avalon GloboCare Corp. do?
  Avalon GloboCare Corp. describes itself as a commercial‑stage company dedicated to developing and delivering precision diagnostic consumer products and advancing intellectual property in cellular therapy. The company is marketing the KetoAir™ breathalyzer device, pursuing additional diagnostic applications of its breathalyzer technology, advancing CAR‑T and CAR‑NK cell intellectual property, operating generative AI publishing and software assets through its Avalon Quantum AI, LLC subsidiary, and owning and operating commercial real estate.
• What is KetoAir™ and how is it used in Avalon’s business?
  KetoAir™ is a handheld breathalyzer designed for ketogenic health management. According to Avalon, it measures breath acetone concentration (BrAce) as an indicator of fat metabolism and ketosis, uses nano‑sensor‑based technology, and is registered with the U.S. Food and Drug Administration as a Class I medical device. Avalon is marketing KetoAir™ as a precision diagnostic consumer product and integrating it into wellness and metabolic‑health programs, including first responder initiatives and affiliate marketing programs.
• How is Avalon involved in cellular therapy?
  Avalon reports that it is advancing intellectual property in cellular therapy, including proprietary CAR‑T and CAR‑NK cell technologies. The company has announced issuance of a standard patent in Hong Kong for CAR‑T and CAR‑NK cell technology co‑developed with Arbele Limited, and notes that this patent complements protections in other jurisdictions under the Patent Cooperation Treaty. Avalon states that it continues to focus on expanding its intellectual property portfolio through existing patent applications.
• What role does generative AI play in Avalon’s operations?
  Through its acquisition of RPM Interactive, Inc., Avalon has added a generative AI publishing and software component to its business. RPM’s Catch‑Up SaaS platform automatically creates short‑form video content by sourcing clips, generating AI commentary, and producing an on‑screen avatar. Avalon has formed Avalon Quantum AI, LLC in connection with this acquisition and indicates that it plans to use the Catch‑Up platform to support marketing for KetoAir™ and other consumer health products.
• Does Avalon own real estate?
  Yes. In its public descriptions, Avalon states that it owns and operates commercial real estate. Earlier segment disclosures refer to a real property operating segment that has been identified as a key revenue driver at that time.
• On which exchange does Avalon GloboCare trade and under what symbol?
  Avalon GloboCare Corp.’s common stock trades on the Nasdaq Capital Market under the ticker symbol ALBT. The company has reported that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement and that its shares continue to be listed and traded on that market.
• What is the relationship between Avalon and YOOV Group Holding Limited?
  Avalon and YOOV Group Holding Limited have entered into an Agreement and Plan of Merger under which a wholly owned Avalon subsidiary will merge with YOOV, with YOOV surviving as a wholly owned direct subsidiary of Avalon. A Registration Statement on Form S‑4 has been filed with the SEC in connection with the proposed merger. According to company communications, the combined business is expected to focus on Artificial Intelligence‑as‑a‑Service (AIaaS) solutions for intelligent business automation, subject to satisfaction of closing conditions.
• What is Avalon doing in cannabis breathalyzer development?
  Avalon, through a definitive agreement with Qi Diagnostics Limited and its subsidiary Q&A Distribution, LLC, is co‑developing a VOC nanosensor‑based point‑of‑care cannabis breathalyzer. The collaboration aims to design, validate, and develop a prototype device intended to support real‑time detection of potential cannabis‑impaired driving and enhance public safety, as described in the company’s June 2025 press release.
• How has Avalon described its historical business segments?
  Earlier descriptions characterize Avalon as an intelligent biotech developer and healthcare service provider with two reportable segments: a real property operating segment and a laboratory testing services segment, with the real property segment cited as a key revenue driver at that time. Over time, company communications have increasingly emphasized precision diagnostic consumer products, cellular therapy intellectual property, generative AI software, and commercial real estate.
• Where is Avalon GloboCare headquartered?
  SEC filings list Avalon GloboCare Corp.’s principal executive offices in Freehold, New Jersey. Filings and press releases consistently reference this city and state in connection with the company’s address.